Induction of Epstein-Barr virus (EBV) reactivation in Raji cells by doxorubicin and cisplatin

Anticancer Research

Volumn 22, Issue 6 C, 2002, Pages 4065-4071

  Hsu, Chih Hung ^a,b   Hergenhahn, Manfred ^d   Chuang, Shuan En ^c   Yeh, Pei Yen ^a,b   Wu, Ta Chung ^b   Gao, Ming ^b   Cheng, Ann Lii ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

12 O Tetradecanoylphorbol 13 acetate (TPA); BMRF 1; BZLF1; Cisplatin; Doxorubicin; Epstein Barr virus (EBV); Viral reactivation; ZEBRA

Indexed keywords

BUTYRIC ACID; CALCIMYCIN; CALCIUM IONOPHORE; CISPLATIN; DOXORUBICIN; IMMUNOGLOBULIN ANTIBODY; PHORBOL 13 ACETATE 12 MYRISTATE; TRANSFORMING GROWTH FACTOR BETA; VIRUS PROTEIN;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; EPSTEIN BARR VIRUS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENE FUNCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAJI CELL; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; TRANSACTIVATION; UPREGULATION; VIRUS INDUCTION; VIRUS REACTIVATION;

ANTIGENS, VIRAL; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; BURKITT LYMPHOMA; CISPLATIN; DNA-BINDING PROTEINS; DOXORUBICIN; GENE EXPRESSION REGULATION, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; LUCIFERASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANS-ACTIVATORS; TUMOR CELLS, CULTURED; UP-REGULATION; VIRAL PROTEINS; VIRUS ACTIVATION;

EID: 0036875694     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Raab-Traub N: Pathogenesis of Epstein-Barr virus and its associated malignancies. Semin Virol 7: 315-323, 1996.
2. Rickinson AB and Kieff E: Epstein-Barr virus. In: Fields Virology, 3 ed (Fields BN, Knipe DM, Howley PM, et al eds). Philadelphia, Lippicott-Raven Publishers, 1996, pp. 2343-2496.
3. Thorley-Lawson DA and Babcock GJ: A model for persistent infection with Epstein-Barr virus: the stealth virus of human B cells. Life Science 65: 1433-1453, 1999.
4. Herbst H: Epstein-Barr virus in Hodgkin's disease. Semin Cancer Biol 7: 183 -189, 1996.
5. Meijer CJ, Jiwa NM, Dukers DF, Oudejans JJ, de Bruin PC, Walboomers JM and van den Brule AJ: Epstein-Barr virus and human T-cell lymphomas. Semin Cancer Biol 7: 191-196, 1996.
6. Niedobitek G, Agathanggelou A and Nicholls JM: Epstein-Barr virus infection and the pathogenesis of nasopharyngeal carcinoma: viral gene expression, tumour cell phenotype, and the role of the lymphoid stroma. Semin Cancer Biol 7: 165-174, 1996.
7. Osato T and Imai S: Epstein-Barr virus and gastric carcinoma. Semin Cancer Biol 7: 175-182, 1996.
8. Young LS: Introduction: Epstein-Barr virus and non-B cell tumours. Semin Cancer Biol 7: 163-164, 1996.
9. zur Hausen H, O'Neill FJ, Freese JK and Hecker E: Persisting oncogenic herpes virus induced by the tumor promoter TP. Nature 272: 373-375, 1978.
10. Ito Y, Kishishita M and Yanase S: Induction of Epstein-Barr virus antigens in human lymphoblastoid P3HR-1 cells with culture fluid of Fusobacteriumtum nucleatum. Cancer Res 40: 4329-4330, 1980.
11. Faggioni A, Zompetta C, Grimaldi S, Barile G, Frati L and Lazdins J: Calcium modulation activates Epstein-Barr virus genome in latently infected cells. Science 232: 1554-1556, 1986.
12. di Renzo L, Altiok A, Klein G and Klein E: Endogenous TGF-beta contributes to the induction of the EBV lytic cycle in two Burkitt lymphoma cell lines. Int J Cancer 57: 914-919, 1994.
13. Tovey MG, Lenoir G and Begon-Lours J: Activation of latent Epstein-Barr virus by antibody to human IgM. Nature 276: 270-272, 1978.
14. Takada K and Ono Y: Synchronous and sequential activation of latently infected Epstein-Barr virus genomes. J Virol 63: 445-449, 1989.
15. Daibata M, Humphreys RE, Takada K and Sairenji T: Activation of latent EBV via anti-IgG-triggered, second messenger pathways in the Burkitt's lymphoma cell line Akata. J Immunol 144: 4788-4793, 1990.
16. Miller G: The switch between latency and replication of Epstein-Barr virus. J Infect Disease 161: 833-844, 1990.
17. Speck SH, Chatila T and Flemingtom E: Reactivation of Epstein-Barr virus: regulation and function of BZLF1 gene. Trends Microbiol 10: 399-405, 1997.
18. Cheng AL, Su IJ, Chen YC, Uen WC and Wang CH: Characteristic clinicopathologic features of Epstein-Barr virus-associated peripheral T-cell lymphoma. Cancer 72: 909-916, 1993.
19. Yao M, Cheng AL, Su IJ, Lin MT, Uen WC, Tien HF, Wang CH and Chen YC: Clinicopathological spectrum of haemophagocytic syndrome in Epstein-Barr virus-associated peripheral T-cell lymphoma. Br J Haematol 87: 535-543, 1994.
20. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B and Craig RW: Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311, 1991.
21. Tishler RB, Calderwood SK, Coleman N and Price BD: Increases in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents. Cancer Res 53: 2212-2216, 1993.
22. Woo RA, McLure KG, Lees-Miller SP, Rancourt DE and Lee PWK: DNA-dependent protein kinase acts upstream of p53 in response to DNA damage. Nature 394: 700-704, 1998.
23. Osborn MT and Chambers TC: Role of the stress-activated/c-Jun NH2-terminal protein kinase pathway in the cellular response to adriamycin and other chemotherapeutic agents. J Biol Chem 172: 30950-30959, 1996.
24. Basu S, Rosenzwei KR, Youmell M and Price BD: The DNA-dependent protein kinase participates in the activation of NF-κB following DNA damage. Biochem Biophys Res Commun 247: 79-83, 1998.
25. Cheng AL, Chuang SE, Lai GM, Liao CM and Hsieh CY: Universal activation of NF-κB by anti-cancer drugs in cancer cell lines. Proc Am Assoc Cancer Res 39: Abstr #1465, 1998.
26. Farrell PJ, Rowe DT, Rooney CM and Kouzarides T: Epstein-Barr virus BZLF1 trans-activator specifically binds to a consensus AP-1 site and is related to c-fos. EMBO J 8: 127-132, 1989.
27. Gutsch DE, Holley-Guthrie EA, Zhang Q, Stein B, Blanar MA, Baldwin AS and Kenney SC: The bZ1P transactivator of Epstein-Barr virus, BZLF1, functionally and physically interacts with the p65 subunit of NF-kappa B. Mol Cell Biol 14: 1939-1948,1994.
28. Hong Y, Holley-Guthrie E and Kenney S: The bZip dimerization domain of the Epstein-Barr virus BZLF1 (Z) protein mediates lymphoid-specific negative regulation. Virol 229: 36-48, 1997.
29. Zhang Q, Gutsch D and Kenney S: Functional and physical interaction between p53 and BZLF1: implication for Epstein-Barr virus latency. Mol Cell Biol 14: 1929-1938, 1994.
30. Polack A, Delius H, Zimber U and Bornkamm GW: Two deletions in the Epstein-Barr virus genome of the Burkitt Lymphoma nonproducer line Raji. Virol 133: 146-157, 1984.
31. Hergenhahn M, Soto U, Weninger A, Polack A, Hsu CH, Cheng AL and Rosl F: The chemopreventive compound curcumin is an efficient inhibitor of Epstein-Barr virus BZLF1 transcription in Raji DR-LUC cells. Mol Carcinogenesis 33: 137-145, 2002.
32. Gibson UE, Heid CA and Williams PM: A novel method for real time quantitative RT-PCR.Genome Res 6: 995-1001, 1996.
33. Heid CA, Stevens J, Livak KJ and Williams PM: Real time quantitative PCR. Genome Res 6: 986-994, 1996.
34. Holland PM, Abramson RD, Watson R and Gelfand DH: Detection of specific polymerase chain reaction product by utilizing the 5'3' exonuclease activity of Thermus aquaticus DNA polymerase. Proc Natl Acad Sci USA 88: 7276-7280, 1991.
35. Novakova Z and Roubal J: Induction of Epstein-Barr virus antigens by hydroxyurea. Acta Virologica 32: 160-163, 1988.
36. Fujita J, Yoshida O, Tokuda H, Sugawara K and Ito Y: Enhanced expression of Epstein-Barr virus early antigens by antitubulin agents in a latently infected human lymphoblastoid cell. Experientia 41: 372-373, 1985.
37. Westphal EM, Blackstock W, Feng W, Israel B and Kenney SC: Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in vitro and in vivo: a potential method for treating EBV-positive malignancies. Cancer Res 60: 5781-5788, 2000.
38. Feng WH, Isael B, Raab-Traub N, Busson P and Kenney SC: Chemotherapy induces lytic EBV replication and confers gancyclovir susceptibility to EBV-positive epithelial cell tumors. Cancer Res 62: 1920-1926, 2002.
39. Kolman RJL, Taylor N, Marshak DR and Miller G: Serine-173 of the Epstein-Barr virus ZEBRA protein is required for DNA binding and is a target for casein kinase II phosphorylation. Proc Natl Acad Sci USA 90: 10115-10119, 1993.
40. Francis A, Gradoville L and Miller G: Alteration of a single serine in the basic domain of the Epstein-Barr virus ZEBRA protein separate its functions of transcriptional activation and disruption of latency. J Virol 71: 3054-3061, 1997.
41. Baumann M, Mischak H, Dammeier S, Kolch W, Gires O, Pich D, Zeidler R, Delecluse HJ and Hammerschidt W: Activation of the Epstein-Barr virus transcription factor BZLF1 by 12-O-tetradecanoylphorbol-13-acetate-induced phosphorylation. J Virol 72: 8105-8114, 1998.
42. Satoh T, Hoshikawa Y, Satoh Y, Kurata T and Sairenji T: The interaction of mitogen-activated protein kinases to Epstein-Barr virus activation in Akata cells. Virus genes 18: 57-64, 1999.
43. Fahmi H, Cochet C, Hmama Z, Opolon P and Joab I: Transforming growth factor beta 1 stimulated expression of the Epstein-Barr virus BZLF1 immediate-early gene product ZEBRA by an indirect mechanism which requires the MAPK kinase pathway. J Virol 74: 5810-5818, 2000.
44. Adamson AL, Darr D, Holley-Guthrie E, Johnson RA, Mauser A, Swenson J and Kenney S: Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate ATF2 transcription factor by increasing the levels of phosphorylation p38 and c-Jun N-terminal kinases. J Virol 74: 1224-1233, 2000.
45. Gao X, Ikuta K, Tajima M and Sairenji T: 12-O-tetradecanoylphorbol-13-acetate induces Epstein-Barr virus reactivation via NF-kappaB and AP-1 as regulated by protein kinase C and mitogen-activated protein kinase K. Virol 286: 91-99, 2001.
46. Redding SW: Role of herpes simplex virus reactivation in chemotherapy-induced oral mucositis. NCI Monographs 9: 103-105, 1990.
47. Liang R, Lau GK and Kwong YL: Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol 17: 394-398, 1999.